Cargando…

Mucosal urinary secretion revealing adenocarcinoma of urachus

INTRODUCTION: Urachus adenocarcinoma is an extremely rare malignant tumor characterized by its insidious evolution responsible for the delay in diagnosis. Several scientific works have tried to study the indication of adjuvant treatment, therefore the prognosis is still poor. PRESENTATION OF CASE: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Jandou, Issam, Ettanji, Adnan, Mohammed, Ettaouil, Moataz, Amine, Mohammed, Dakir, Debbagh, Adil, Aboutaieb, Rachid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093895/
https://www.ncbi.nlm.nih.gov/pubmed/33996065
http://dx.doi.org/10.1016/j.amsu.2021.102335
Descripción
Sumario:INTRODUCTION: Urachus adenocarcinoma is an extremely rare malignant tumor characterized by its insidious evolution responsible for the delay in diagnosis. Several scientific works have tried to study the indication of adjuvant treatment, therefore the prognosis is still poor. PRESENTATION OF CASE: We report the case of a 50-year-old patient with no pathological history who consulted for an episode of intermittent urinary mucosal secretion aggravated by the appearance of macroscopic hematuria. Without other associated clinical signs. Imaging examinations revealed a mass at the expense of the upper wall of the bladder. The cystoscopy allowed us to visualize the mass and the biopsy. Histological study revealed an adenocarcinoma of urachus. The patient underwent surgical exeresis and adjuvant chemotherapy. The evolution was marked by a deterioration of the general condition despite adequate management. DISCUSSION: Due to its topography, urachus cancer usually manifests as a bladder tumor, exceptionally as much as an anterior umbilical or extraperitoneal tumor. Few studies have been done on this neoplasm; however surgery still has a primary place in therapeutic management. CONCLUSION: The scarcity of cases of urachus cancer makes the publications scarce and the lack of multicenter clinical and randomized trials explains the disagreement about adjuvant treatments.